Latest news

Latest News

First RESCEU’s Clinical Studies patients tested

RESCEU’s clinical studies have started, with the aim of gathering data and addressing knowledge gaps on the impact of RSV infections. The investigation is building on the knowledge of a varied team of partners from universities and public health institutions, and includes 3 cohort studies on vulnerable populations (infants, older adults, COPD subjects) and one …

RESCEU becomes ISARIC member

We are glad to announce the RESCEU membership in the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). It is a global initiative aiming to ensure that clinical researchers have the open access protocols and data-sharing processes needed to facilitate a rapid response to emerging diseases that may turn into epidemics or pandemics. Please follow …

Kick off meeting

After many months of intensive preparatory work following a competitive call process, the Respiratory Syncytial Virus Consortium in Europe (RESCEU) was launched in January 2017. The RESCEU project aims to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, …

€29m research grant to assess risk posed by deadly lung infections

Experts have received €29 million (£24m) to investigate serious lung infections that particularly affect babies and older people. Diseases caused by respiratory syncytial virus (RSV) are estimated to affect more than 30 million children under five each year throughout the world. The virus also affects older people and those with weakened immune systems, including cancer …